Screener
Ginkgo Bioworks DNA Cell Engineering — Concentration risk
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:ConcentrationRiskPercentage1.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Government and defense | 45% | 21% | 41% | 19% |
| Pharmaceutical and biotechnology | 20 | 44 | 29 | 38 |
| Agriculture | 20 | 23 | 16 | 32 |
| Food and nutrition | 7 | 6 | 7 | 5 |
| Consumer and technology | 6 | 2 | 3 | 1 |
| Industrial and environment | 2 | 4 | 4 | 5 |
| Total revenue | 100% | 100% | 100% | 100% |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ginkgo Bioworks's cell engineering — concentration risk?
- Ginkgo Bioworks (DNA) reported cell engineering — concentration risk of 100% in Q2 2026.
- How has Ginkgo Bioworks's cell engineering — concentration risk changed year-over-year?
- Ginkgo Bioworks's cell engineering — concentration risk decreased by 0.0% year-over-year, from 100% to 100%.
- What does cell engineering — concentration risk mean?
- This metric assesses the overall exposure of the cell engineering segment to specific market sectors, technologies, or customer bases. It serves as a qualitative and quantitative measure of the potential impact that a downturn in a specific area could have on the segment's performance.
Ask your AI about Ginkgo Bioworks's cell engineering — concentration risk.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude